The propelling factors for the growth of the global protein engineering market include the increasing prevalence of protein-deficient diseases, the increase in adoption of protein drugs over non-protein drugs, increased demand for alternatives to chemical processes, and rising government funding for protein engineering.

Protein-energy malnutrition (PEM) is increasing in the rural areas of emerging economies. It refers to a group of disorders that include marasmus, kwashiorkor, and intermediate states of marasmus-kwashiorkor. Therefore, the prevalence of kwashiorkor varies across geographies. It is rare in the United States. However, some of the affected regions include Southeast Asia, Central America, Congo, Puerto Rico, Jamaica, and South Africa. Thus, the increasing prevalence of protein-deficient diseases is driving the demand for the overall market.

There is a rising number of government initiatives, such as funding R&D for protein engineering and awareness programs, which influenced the healthcare industry. Thus, the government is proactively investing in many of the research studies. For instance, Protein Technologies Ltd (PTL) received funding from the UK government’s Technology Strategy Board (now Innovate UK), for its innovative research in protein engineering. Hence, the increasing number of government initiatives for the efficient protein engineering research helps in driving the overall growth of the market.

Protein engineering also holds an immense opportunity in the agrochemical industry, as engineering in proteins may lead to the generation of enzymes with improved function, that may increase the crop yield or facilitate the biofuel production. It is also likely to play an important role as a tool, to attain increased crop yield needed to meet future demands.

Key Market Trends

Monoclonal Antibodies by Protein Type is Expected to be Largest Contributor in the Market over the Forecast Period

Monoclonal antibodies are anticipated to hold the largest market share over the forecast period, owing to their high adoption for numerous therapies, such as cancer and autoimmune diseases. The increasing prevalence of cancer and other autoimmune diseases has significantly increased the use of monoclonal bodies for the treatment of diseases. They also have tremendous applications in the fields of therapeutics, diagnostics, and targeted drug delivery systems, for infectious diseases caused by viruses, bacteria, protozoa, metabolic and hormonal disorders. Hence, recombinant deoxyribonucleic acid technology, through genetic engineering, has successfully led to the possibility of reconstruction of monoclonal antibodies, in turn, fueling the growth of the segment.

Asia-Pacific Witnessed the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period

Asia-Pacific is expected to witness the fastest CAGR during the forecast period, owing to the growing presence of contract research organizations, rising healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards across the region. Growing demand for personalized medicine and strong R&D investments in proteomics-based drug discovery projects are also supplementing the growth of the protein engineering market.

Competitive Landscape

The protein engineering market players are highly focused on strategies, such as mergers and acquisitions, new product development initiatives, and geographical expansion. As the cost of R&D is high and requires high-end infrastructure, most of the pharmaceutical and biotechnology companies are moving toward CROs. Most of the players in the CRO industry are joining forces, in order to create a market position.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support